BI Asset Management Fondsmaeglerselskab A S Has $41.90 Million Holdings in GSK PLC Sponsored ADR $GSK

BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 2,032.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 854,331 shares of the pharmaceutical company’s stock after buying an additional 814,275 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in GSK were worth $41,896,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Fisher Asset Management LLC boosted its position in shares of GSK by 2.8% during the third quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company’s stock worth $1,390,944,000 after buying an additional 889,210 shares during the period. Brighton Jones LLC acquired a new stake in shares of GSK in the fourth quarter valued at $528,000. Prime Capital Investment Advisors LLC boosted its holdings in GSK by 182.7% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 30,188 shares of the pharmaceutical company’s stock valued at $1,480,000 after purchasing an additional 19,509 shares during the period. Farther Finance Advisors LLC boosted its holdings in GSK by 146.6% in the fourth quarter. Farther Finance Advisors LLC now owns 29,529 shares of the pharmaceutical company’s stock valued at $1,448,000 after purchasing an additional 17,553 shares during the period. Finally, PFA Pension Forsikringsaktieselskab purchased a new position in GSK in the fourth quarter valued at $6,385,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Up 0.6%

Shares of GSK stock opened at $51.57 on Friday. GSK PLC Sponsored ADR has a 1 year low of $35.45 and a 1 year high of $61.69. The company has a market capitalization of $104.64 billion, a P/E ratio of 13.40, a PEG ratio of 2.63 and a beta of 0.36. The company’s fifty day moving average is $53.44 and its two-hundred day moving average is $52.51. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Shareholders of record on Friday, May 15th will be given a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Friday, May 15th. GSK’s dividend payout ratio (DPR) is presently 47.01%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on GSK shares. Citigroup reiterated a “neutral” rating on shares of GSK in a report on Monday, February 9th. Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Weiss Ratings upgraded GSK from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday, May 1st. TD Cowen reiterated a “hold” rating on shares of GSK in a report on Monday, February 9th. Finally, Barclays reiterated an “underweight” rating on shares of GSK in a report on Friday, February 20th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $53.00.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.